Quotables
"Flight by machines heavier than air is unpractical and insignificant, if not utterly impossible."
Simon Newcomb, astronomer ; Said in 1902, less than two years before the first flight at Kitty Hawk
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8431606 | Medicament for treating schizophrenia comprising cilostazol The invention relates to a medicament for preventing and/or treating schizophrenia which comprises as an active ingredient cilostazol or a pharmaceutically acceptable salt thereof. ... | 04/30/2013 |
| 8410154 | Tetrazole compounds for reducing uric acid Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including gout, hyperu... | 04/02/2013 |
| 8404730 | 3-substituted propanamine compounds Racemic or enantiomerically enriched 3-substituted propanamine compounds represented by the following structural formula (I): or a pharmaceutically acceptable salt thereof are disclosed. Pharmaceutical compositions containi... | 03/26/2013 |
| 8394846 | Dual-acting antihypertensive agents The invention is directed to compounds of formula I: wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have A... | 03/12/2013 |
| 8394844 | EP4 agonist Provided is a compound represented by the formula (1): wherein R1 and R2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, R3 is a hydroge... | 03/12/2013 |
| 8394845 | Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor Disclosed herein is a combination therapy and a combination preparation of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor characterized in that the angiotensin-II-receptor blocker is absorbed substantially later than the HMG-CoA reductase inhi... | 03/12/2013 |
| 8383660 | Dibenzyl amine compounds and derivatives Dibenzyl amine compounds and derivatives of Formula I, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid ... | 02/26/2013 |
| 8377978 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R6, A1, A2, X1... | 02/19/2013 |
| 8367710 | Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof The bicyclo-substituted pyrazolon-azo derivatives of formula (I) or pharmaceutical acceptable salts, hydrates or solvates thereof, methods for their preparation, pharmaceutical compositions containing the same and their use as a therapeutic agent, especially as thro... | 02/05/2013 |
| 8367709 | Dipeptide analogs as coagulation factor inhibitors Disclosed are novel dipeptide analogs compounds of Formula (I), (II) or (III): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate, or a prodrug thereof, which are inhibitors of factor XIa and/or pl... | 02/05/2013 |
| 8367711 | Angiotensin II receptor antagonists A compound having the structure wherein R is, for example, Y is selected from the group consisting of 1) R5, 2) —C(R1R2) (C(R3R4))0-1Y1R5, and 3) —C(R1R2)—O—Y1R5; R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen and C1-4 alk... | 02/05/2013 |
| 8362054 | Therapeutic substituted lactams Therapeutic compounds, compositions, methods, and medicaments related thereto are disclosed herein. ... | 01/29/2013 |
| 8361959 | Spiro-imidazolone derivatives as glucagon receptor antagonists The present invention relates to compounds of the general formula: (I) wherein ring A, ring B, R1, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compou... | 01/29/2013 |
| 8293776 | Compositions and methods for treating inflammatory conditions of the bowel The present invention provides compositions and methods for treating inflammatory conditions (e.g., of the bowel). In particular, the present invention provides methods of treating (e.g., therapeutically and/or prophylactically treating) inflammatory conditions (e.g... | 10/23/2012 |
| 8278339 | Valsartan salts The invention relates to new salts of valsartan or crystalline, also partly crystalline and amorphous salts of valsartan, the respective production and usage, and pharmaceutical preparations containing such a salt. ... | 10/02/2012 |
| 8273781 | Process for preparation of 1-alkyl-5-benzoyl-1H-tetrazole derivatives The present invention provides a process for preparation of 1-alkyl-5-benzoyl-1H-tetrazole derivative including a step 1 of reacting a ketoamide derivative represented by formula (I) (in formula (I), A represents a halogen atom or the like; n represents an integer o... | 09/25/2012 |
| 8252826 | Cyclopentyl- and cycloheptylpyrazoles This invention relates to novel cyclopentyl- and cycloheptylpyrazole derivatives of the formula I wherein A and R1 to R4 are as defined in the description and in the claims, as well as physiologically ... | 08/28/2012 |
| 8252825 | Angiotensin II receptor antagonists A compound having the structure wherein R is an angiotensin receptor antagonist active group, and Y is 1) —(CH2)3R5, 2) —C(O)(CH2)2R5... | 08/28/2012 |
| 8236839 | Dual-acting antihypertensive agents The invention relates to compounds having the formula: wherein: Ar, r, R3, Z, X, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT | 08/07/2012 |
| 8222286 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors The present invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R6, A1, A2, X1... | 07/17/2012 |
| 8217067 | Amino-tetrazoles analogues and methods of use A compound having Formula (I) or Formula (II) is disclosed as an P2X7 antagonist, wherein A, B, C, Y, Y, Z, m, v, R1, R2, R3, R4, and R5 | 07/10/2012 |
| 8207208 | Angiotensin II receptor antagonists A compound having the structure R—Y wherein R is, for example, Y is selected from the group consisting of 1) R5, 2) —C(R1... | 06/26/2012 |
| 8202896 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infection. ... | 06/19/2012 |
| 8193226 | Candesartan cilexetil Candesartan cilexetil-containing granules which include a sugar alcohol and a binder and which are produced by granulation with an alcoholic granulating liquid. The granules are suitable for producing tablets in which the candesartan cilexetil is present in a form s... | 06/05/2012 |
| 8183272 | Indanyl compounds Compounds exhibiting calcium receptor antagonist activity that are safe and orally administrable having Formula (I) or pharmaceutically acceptable salts thereof: ... | 05/22/2012 |
| 8183271 | Tetrazole derivatives and their use for the treatment of cardiovascular diseases The present application relates to novel tetrazole derivatives, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, especially for the ... | 05/22/2012 |
| 8178569 | Crystalline imidazole-5-carboxylic acid derivative The invention provides the crystalline imidazole-5-carboxylic acid derivative (I, the chemical name: 2-butyl-4-chloro-1-[2′-(1H-tetrazol-5-yl) 1,1′-biphenyl-methyl]-imidazole-5-carboxylic acid, 1-[(isopropoxy)-carbonyloxy]methyl ester), its preparation method an... | 05/15/2012 |
| 8163786 | Preparation of a lead-free primary explosive Embodiments of the present subject matter provide a compound and material that may be used as a lead-free primary explosive. An embodiment of the present subject matter provides the compound copper(I) nitrotetrazolate. Certain embodiments of the present subject matt... | 04/24/2012 |
| 8153670 | Factor Xa inhibitors The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such... | 04/10/2012 |
| 8143298 | Dual-acting antihypertensive agents The invention is directed to compounds of formula I: wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have A... | 03/27/2012 |
| 8138214 | Pharmaceutical composition The invention provides a new pharmaceutical compositions for treating cardiovascular disease, which contains the active component 2-butyl-4-chloro-1-[2′-(1H-tetrazol-5-yl)1,1′-biphenyl-methyl]imidazole-5-carboxylic acid, 1-[(isopropoxy)carbonyloxy]methyl ester d... | 03/20/2012 |
| 8124634 | CB1 receptor modulators Compounds of formula (I) suppress the normal signalling activity CB1 receptors, and are thus useful in the treatment of diseases or conditions which are mediated by CB1 receptor signalling activity, such as treatment of obesity and overweight, prevention of weigh ga... | 02/28/2012 |
| 8119672 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infections. ... | 02/21/2012 |
| 8119673 | Compounds 148 This invention relates to novel pharmaceutically useful compounds of formula (I), in particular compounds that are competitive inhibitors of trypsin-like serine proteases, especially thrombin, their use as medicaments, pharmaceutical compositions containing them and... | 02/21/2012 |
| 8106082 | Dual-acting antihypertensive agents The invention relates to compounds having the formula: wherein: Ar, r, R3, Z, X, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT | 01/31/2012 |
| 8106081 | Combination of organic compounds useful for treating diabetes The present invention relates to a combination, especially a pharmaceutical composition, comprising as active ingredients (i) an AT1-receptor antagonist or a pharmaceutically acceptable salt thereof; (ii) (a) an insulin secretion... | 01/31/2012 |
| 8101642 | 3-substituted propanamine compounds Racemic or enantiomerically enriched 3-substituted propanamine compounds represented by the following structural formula (I): or a pharmaceutically acceptable salt thereof are disclosed. Pharmaceutical compositions containi... | 01/24/2012 |
| 8097639 | Light sensitive PDMS for complex pattern formation Disclosed herein is a surface functionalized poly(dimethylsiloxane) (PDMS) and methods for making the same. The surface functionalized PDMS disclosed herein is applicable in the general field of microfluidics, bioMEMS (bio-microelectromechanical systems), soft litho... | 01/17/2012 |
| 8088809 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, and/or cardiometabolic disorders. ... | 01/03/2012 |
| 8063082 | Certain chemical entities, compositions, and methods Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described. ... | 11/22/2011 |
